Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
2.890
+0.060 (2.12%)
At close: Nov 20, 2024, 4:00 PM
2.810
-0.080 (-2.77%)
Pre-market: Nov 21, 2024, 7:41 AM EST
Vivos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 14.58 | 13.8 | 16.02 | 16.89 | 13.07 | 11.39 | Upgrade
|
| Revenue Growth (YoY) | 0.54% | -13.87% | -5.10% | 29.23% | 14.68% | 200.43% | Upgrade
|
| Cost of Revenue | 5.57 | 5.53 | 6.01 | 4.28 | 2.65 | 2.74 | Upgrade
|
| Gross Profit | 9.01 | 8.27 | 10.02 | 12.6 | 10.41 | 8.66 | Upgrade
|
| Selling, General & Admin | 20.82 | 24.85 | 34.18 | 31.34 | 18.4 | 18.48 | Upgrade
|
| Research & Development | 0.1 | 0.1 | 0.2 | - | - | - | Upgrade
|
| Operating Expenses | 21.51 | 25.57 | 35.05 | 32.08 | 19.12 | 19.23 | Upgrade
|
| Operating Income | -12.5 | -17.3 | -25.03 | -19.47 | -8.71 | -10.58 | Upgrade
|
| Interest Expense | - | - | - | -0.01 | -0.1 | -0.14 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0.08 | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.07 | 3.71 | -0.1 | 0.11 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -12.57 | -13.58 | -25.13 | -19.38 | -8.73 | -10.69 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.06 | Upgrade
|
| Asset Writedown | - | - | - | -0.91 | - | - | Upgrade
|
| Other Unusual Items | - | - | 1.29 | - | -3.33 | - | Upgrade
|
| Pretax Income | -12.57 | -13.58 | -23.85 | -20.29 | -12.06 | -10.75 | Upgrade
|
| Net Income | -12.57 | -13.58 | -23.85 | -20.29 | -12.06 | -10.75 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 5.93 | 1 | Upgrade
|
| Net Income to Common | -12.57 | -13.58 | -23.85 | -20.29 | -17.99 | -11.75 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 1 | 1 | 1 | 1 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 1 | 1 | 1 | 1 | 0 | Upgrade
|
| Shares Change (YoY) | 210.69% | 32.46% | 8.39% | 65.00% | 4.36% | 6.78% | Upgrade
|
| EPS (Basic) | -3.52 | -11.14 | -25.90 | -23.89 | -34.94 | -23.83 | Upgrade
|
| EPS (Diluted) | -3.52 | -11.14 | -25.90 | -23.89 | -34.94 | -23.83 | Upgrade
|
| Free Cash Flow | -13.07 | -12.8 | -20.51 | -18.13 | -5.8 | -5.52 | Upgrade
|
| Free Cash Flow Per Share | -3.66 | -10.50 | -22.28 | -21.35 | -11.27 | -11.18 | Upgrade
|
| Gross Margin | 61.80% | 59.93% | 62.52% | 74.65% | 79.70% | 75.99% | Upgrade
|
| Operating Margin | -85.71% | -125.32% | -156.21% | -115.32% | -66.65% | -92.84% | Upgrade
|
| Profit Margin | -86.19% | -98.42% | -148.81% | -120.15% | -137.67% | -103.17% | Upgrade
|
| Free Cash Flow Margin | -89.62% | -92.74% | -128.00% | -107.38% | -44.39% | -48.42% | Upgrade
|
| EBITDA | -11.91 | -16.68 | -24.36 | -18.74 | -7.99 | -9.83 | Upgrade
|
| EBITDA Margin | -81.70% | -120.82% | -152.03% | -110.97% | -61.16% | -86.24% | Upgrade
|
| D&A For EBITDA | 0.59 | 0.62 | 0.67 | 0.73 | 0.72 | 0.75 | Upgrade
|
| EBIT | -12.5 | -17.3 | -25.03 | -19.47 | -8.71 | -10.58 | Upgrade
|
| EBIT Margin | -85.71% | -125.32% | -156.21% | -115.32% | -66.65% | -92.84% | Upgrade
|
| Revenue as Reported | 14.58 | 13.8 | 16.02 | 16.89 | 13.07 | 11.39 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.